Bailard’s Wave Life Sciences WVE Stock Holding History

Bailard’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-80,000	Closed	-$8K	–	578
2019 Q4	$8K	Buy	+80,000	New	+$1.96M	﹤0.01%	535

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bailard's WVE Position: Q4 2019 in Review

Bailard sold out of Wave Life Sciences (WVE) in Q4 2019, closing a stake of 85,000 shares — an estimated $2.08M sold.

Bailard first reported a position in WVE in Q4 2017 and held it in 8 quarters. The position peaked at $2.77M in Q4 2017. 90 funds tracked by Wall St. Rank hold WVE as of Q4 2019.

Bailard reported no remaining Wave Life Sciences position as of Q4 2019 after selling out during the quarter.
Bailard sold 85,000 Wave Life Sciences shares in Q4 2019, an estimated $2.08M.
Bailard first reported a position in Wave Life Sciences in Q4 2017 and held it in 8 quarters.
Bailard's Wave Life Sciences position peaked at $2.77M in Q4 2017.
90 funds tracked by Wall St. Rank held Wave Life Sciences as of Q4 2019.

Based on Bailard's 13F filing for Q4 2019, filed 31 Jan 2020.